Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: £10.14 per share
- Transaction Type: Increase in ordinary share interests via dividend re-investment
- Dividend Date: April 9, 2009
Material Changes
The filing reports specific increases in shareholdings for four individuals following the re-investment of dividends paid on April 9, 2009. No material changes to the company's financial position or operations are disclosed in this document.
- Mr E J Gray: 381.25 shares
- Mr S A Hussain: 683.37 shares
- Mr D S Redfern: 301.60 shares
- Ms C Thomas: 188.50 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors post-transaction.
- Confirm the dividend amount per share implied by the re-investment at £10.14.
- Check subsequent filings for broader financial performance data not included in this specific 6-K.